Literature DB >> 28032956

Efficacy and safety of propranolol for epistaxis in hereditary haemorrhagic telangiectasia: retrospective, then prospective study, in a total of 21 patients.

A Contis1, N Gensous1, J F Viallard2, C Goizet3, C Léauté-Labrèze4, P Duffau1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28032956     DOI： 10.1111/coa.12821

Source DB:  PubMed          Journal:  Clin Otolaryngol        ISSN： 1749-4478            Impact factor:   2.597


× No keyword cloud information.
  3 in total

1.  Using Esterase Selectivity to Determine the In Vivo Duration of Systemic Availability and Abolish Systemic Side Effects of Topical β-Blockers.

Authors:  Jillian G Baker; Christophe Fromont; Marjorie Bruder; Kevin S J Thompson; Barrie Kellam; Stephen J Hill; Sheila M Gardiner; Peter M Fischer
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-01

2.  Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia - a preliminary report.

Authors:  Meir Mei-Zahav; Hannah Blau; Elchanan Bruckheimer; Eyal Zur; Neta Goldschmidt
Journal:  J Otolaryngol Head Neck Surg       Date:  2017-10-04

3.  Long-term efficacy assessment of current treatment options for epistaxis in HHT.

Authors:  Cilgia Dür; L Anschuetz; S Negoias; O C Bulut; A Angelillo-Scherrer; M Caversaccio
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-03-04       Impact factor: 2.503
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.